Considering the provisions of the PRAC Report on the Periodic Safety Update Reports (PSURs) for glimepiride/pioglitazone hydrochloride, metformin/pioglitazone, pioglitazone, the scientific conclusions of the CHMP are as follows:
The TAC provided updated information related to the identified and potential important risks, as listed in the summary of safety problems. The data presented during the current reporting period did not provide new information that would allow the reduction, mitigation, or characterization of these risks. According to the data presented, the risk minimization measures approved in the product information are considered adequate for the safety problems listed.
Given the accumulation of data since the implementation of additional risk minimization measures, the PRAC accepted the TAC's proposal to eliminate the additional risk minimization measures. As a consequence, the conditions or restrictions related to the safe and effective use of the medicine should be updated to eliminate the additional risk minimization measures. The PSUR has been updated accordingly.
The CHMP agrees with the scientific conclusions of the PRAC.
Reasons for the modification of the conditions of the Marketing Authorisation(s)
According to the scientific conclusions for glimepiride/pioglitazone hydrochloride, metformin/pioglitazone, pioglitazone, the CHMP considers that the benefit-risk balance of the medicine or medicines containing glimepiride/pioglitazone hydrochloride, metformin/pioglitazone, pioglitazone is not modified subject to the proposed changes in the product information.
The CHMP recommends that the conditions of the Marketing Authorisation(s) be modified.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.